Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, and others.
DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the Small Lymphocytic Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Lymphocytic Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Small Lymphocytic Lymphoma Pipeline Report
- DelveInsight’s Small Lymphocytic Lymphoma Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline treatment therapies.
- The leading Small Lymphocytic Lymphoma Companies working in the market include Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others
- Promising Small Lymphocytic Lymphoma Pipeline Therapies in the various stages of the development include Pirtobrutinib, Bendamustine, Rituximab, Venetoclax, LOXO-305, ABT-199, ofatumumab, TG02 citrate, and others.
- November 2023: AbbVie announced a study of Phase 2 clinical trials for Venetoclax and Obinutuzumab. A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia.
- November 2023: Loxo Oncology Inc. announced a study of Phase 3 clinical trials for LOXO-305 and Idelalisib. This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.
- November 2023: AstraZeneca announced a study of Phase 3 clinical trials for Acalabrutinib. This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: treatment-naive (TN), relapsed/refractory (R/R), and prior ibrutinib therapy. For this study, participants in the UK will be enrolled ONLY into the R/R cohort or the prior ibrutinib cohort. Participants in the US will be enrolled ONLY into the TN or R/R cohort.
Request a sample and discover the recent advances in Small Lymphocytic Lymphoma Treatment Drugs @ Small Lymphocytic Lymphoma Pipeline Report
In the Small Lymphocytic Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Lymphocytic Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Small Lymphocytic Lymphoma Overview
Small Lymphocytic Lymphoma is an indolent (slow growing) non-Hodgkin lymphoma that affects B cells. B cells (also known as B lymphocytes) are specialized white blood cells. Under normal conditions they produce immunoglobulins (also called antibodies) that help protect our bodies against infection and disease. Small lymphocytic lymphoma is considered part of the same disease process as CLL; however, the disease is known as SLL when it involves a lymph node, and CLL when it involves the peripheral blood.
Find out more about Small Lymphocytic Lymphoma Treatment Landscape @ Drugs for Small Lymphocytic Lymphoma Treatment
Small Lymphocytic Lymphoma Emerging Drugs Profile
- TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
- LOXO-305: Loxo Oncology
- IOV 2001: Iovance Biotherapeutics
Small Lymphocytic Lymphoma Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies for Small Lymphocytic Lymphoma. The Small Lymphocytic Lymphoma companies which have their Small Lymphocytic Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Loxo Oncology.
DelveInsight’s Small Lymphocytic Lymphoma pipeline report covers around 80+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Small Lymphocytic Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Small Lymphocytic Lymphoma Pipeline Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Learn more about the emerging Small Lymphocytic Lymphoma Pipeline Therapies @ Small Lymphocytic Lymphoma Clinical Trials Assessment
Scope of the Small Lymphocytic Lymphoma Pipeline Report
- Coverage- Global
- Small Lymphocytic Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Small Lymphocytic Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Small Lymphocytic Lymphoma Companies- Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others
- Small Lymphocytic Lymphoma Pipeline Therapies- Pirtobrutinib, Bendamustine, Rituximab, Venetoclax, LOXO-305, ABT-199, ofatumumab, TG02 citrate, and others.
Dive deep into rich insights for new drugs for Small Lymphocytic Lymphoma treatment, Visit @ Small Lymphocytic Lymphoma Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Small Lymphocytic Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Small Lymphocytic Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Pre-Registration)
- Drug Name : Company Name
- Drug profiles in the detailed report…..
- Last Stage Products (Phase III)
- LOXO-305: Loxo Oncology
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Small Lymphocytic Lymphoma Key Companies
- Small Lymphocytic Lymphoma Key Products
- Small Lymphocytic Lymphoma – Unmet Needs
- Small Lymphocytic Lymphoma – Market Drivers and Barriers
- Small Lymphocytic Lymphoma – Future Perspectives and Conclusion
- Small Lymphocytic Lymphoma Analyst Views
- Small Lymphocytic Lymphoma Key Companies
- Appendix
For further information on the Small Lymphocytic Lymphoma pipeline therapeutics, reach out @ Small Lymphocytic Lymphoma Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market
